CytoReason built a machine learning platform that can quantify a person’s immune system in order to better understand disease responses.

CytoReason will profile one of the German multinational science and technology company's leading immuno-oncology drugs.

Israeli AI company Cytoreason develops computational disease models of the human immune system for discovery and clinical drug development.

CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.

Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.

The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.